BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Novartis readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Novartis's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06991556-10762@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Luxdegalutamide: Phase 2 readout est. (NCT06991556)
DESCRIPTION:Luxdegalutamide\, phase 2.\nStudy: An Open-label Study of JSB46
 2 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients
  With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)\nEstimated prim
 ary completion: 3 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/luxdegalutamide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06991556
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06388941-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Fabhalta (Iptacopan): Phase 2 readout est. (NCT06388941)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 2.\nStudy: Iptacopan in Patients W
 ith ANCA Associated Vasculitis\nEstimated primary completion: 30 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iptacopan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06388941
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102628-1034@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT07102628)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Evaluation of Efficacy and Safety of Early in Hospital In
 itiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
 \nEstimated primary completion: 16 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07102628
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05038735-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270128
DTEND;VALUE=DATE:20270129
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT05038735)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulv
 estrant in Participants With HR-positive (HR+)\, HER2-negative\, Advanced 
 Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inh
 ibitor.\nEstimated primary completion: 28 January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05038735
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04544189-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04544189)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study Assessing the Efficacy and Safety of Treatment With Alpe
 lisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and 
 Postmenopausal Women With Advanced Breast Cancer\nEstimated primary comple
 tion: 29 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/alpelisib-byl719#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04544189
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817618-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04817618)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Study of Efficacy and S
 afety of Iptacopan in Patients With C3 Glomerulopathy.\nEstimated primary 
 completion: 29 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iptacopan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04817618
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02934568-2228@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Ribociclib: Phase 2 readout est. (NCT02934568)
DESCRIPTION:Ribociclib\, phase 2.\nStudy: Ribociclib (LEE011) Rollover Stud
 y for Continued Access\nEstimated primary completion: 1 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02934568
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04417621-1979@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Trametinib: Phase 2 readout est. (NCT04417621)
DESCRIPTION:Trametinib\, phase 2\, Melanoma.\nStudy: Study of Efficacy and 
 Safety of LXH254 Combinations in Patients With Previously Treated Unresect
 able or Metastatic Melanoma\nEstimated primary completion: 2 February 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04417621
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811908-11260@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Cipargamin: Phase 2 readout est. (NCT07811908)
DESCRIPTION:Cipargamin\, phase 2\, Malaria.\nStudy: Platform Study to Evalu
 ate the Efficacy and Safety of Anti-malarial Agents in Participants With U
 ncomplicated Plasmodium Falciparum Malaria (Cohort C2)\nEstimated primary 
 completion: 4 February 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cipargamin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07811908
URL:https://assetmemo.bio/drug/cipargamin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868212-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06868212)
DESCRIPTION:remibrutinib\, phase 3\, Chronic Spontaneous Urticaria.\nStudy:
  A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Ear
 ly Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Co
 ntrolled by Second Generation H1-antihistamines\nEstimated primary complet
 ion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/remibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06868212
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01872260-2228@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT01872260)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of LEE011\, BYL719 and Letrozole in Advanced ER+ Breast Cancer
 \nEstimated primary completion: 26 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT01872260
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524000-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04524000)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Study Assessing the Efficacy and Safety of Treatment With Alpe
 lisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advan
 ced Breast Cancer\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04524000
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208178-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Alpelisib (BYL719): Phase 3 readout est. (NCT04208178)
DESCRIPTION:Alpelisib (BYL719)\, phase 3\, Breast Cancer.\nStudy: Study of 
 Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maint
 enance Therapy in Patients With HER2-positive Advanced Breast Cancer With 
 a PIK3CA Mutation\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04208178
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02962414-9023@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Everolimus: Phase 3 readout est. (NCT02962414)
DESCRIPTION:Everolimus\, phase 3\, Epilepsy.\nStudy: Roll-over Study to Col
 lect and Assess Long-term Safety of Everolimus in Patients With TSC and Re
 fractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and 
 Who Are Benefitting From Continued Treatment\nEstimated primary completion
 : 26 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 verolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02962414
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249463-11251@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:EDI048: Phase 2 readout est. (NCT07249463)
DESCRIPTION:EDI048\, phase 2\, Cryptosporidiosis.\nStudy: Study Testing the
  Efficacy\, Safety\, and Tolerability of EDI048 in Cryptosporidium Infecti
 on Model in Healthy Adults\nEstimated primary completion: 23 March 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/edi048#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07249463
URL:https://assetmemo.bio/drug/edi048#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05639114-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:VAY736: Phase 3 readout est. (NCT05639114)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Study to Evaluate Two Regimen
 s of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemi
 c Lupus Erythematosus (SIRIUS-SLE 1)\nEstimated primary completion: 26 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05639114
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624749-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:VAY736: Phase 3 readout est. (NCT05624749)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Study to Evaluate Ianalumab o
 n Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythema
 tosus (SIRIUS-SLE 2)\nEstimated primary completion: 12 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05624749
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203001-11265@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270422
DTEND;VALUE=DATE:20270423
SUMMARY:Arumakimig: Phase 2 readout est. (NCT07203001)
DESCRIPTION:Arumakimig\, phase 2\, Still's Disease.\nStudy: A Phase II Tria
 l to Evaluate the Clinical Efficacy\, Safety and Tolerability of MAS825 in
  Pediatric and Adult Participants With Still's Disease\nEstimated primary 
 completion: 22 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/arumakimig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07203001
URL:https://assetmemo.bio/drug/arumakimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235046-1076@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270426
DTEND;VALUE=DATE:20270427
SUMMARY:BW-20829: Phase 2 readout est. (NCT07235046)
DESCRIPTION:BW-20829\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Study of DII235 in Adults With Elevated Lipoprotein(a)\nEstimated 
 primary completion: 26 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bw-20829#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07235046
URL:https://assetmemo.bio/drug/bw-20829#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517758-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06517758)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Generalized Myasthenia Gravis.
 \nStudy: A Phase III Study to Investigate Efficacy\, Safety and Tolerabili
 ty of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years 
 With gMG.\nEstimated primary completion: 30 April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06517758
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05030428-1034@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05030428)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study of Inclisiran to Prevent Cardiovascular (CV) Events
  in Participants With Established Cardiovascular Disease\nEstimated primar
 y completion: 10 May 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05030428
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220577-1372@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:GIA632: Phase 2 readout est. (NCT07220577)
DESCRIPTION:GIA632\, phase 2\, Atopic Dermatitis.\nStudy: Phase 2a Study to
  Assess the Efficacy\,Safety and Tolerability of GIA632 in Adult Participa
 nts With Moderate to Severe Atopic Dermatitis\nEstimated primary completio
 n: 17 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gia63
 2#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 220577
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799000-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06799000)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva (RECHARGE 1)\nEstimated primary completion: 17 May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06799000
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067140-10762@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Luxdegalutamide: Phase 1/2 readout est. (NCT05067140)
DESCRIPTION:Luxdegalutamide\, phase 1/2.\nStudy: A Study of ARV-766 Given b
 y Mouth in Men With Metastatic Prostate Cancer\nEstimated primary completi
 on: 25 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/luxd
 egalutamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05067140
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840392-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270603
DTEND;VALUE=DATE:20270604
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06840392)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva\nEstimated primary completion: 3 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/remibrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06840392
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04980833-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT04980833)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: Study Assessing Long-term
  Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrow
 th Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPI
 K-P1)\nEstimated primary completion: 22 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04980833
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03960840-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT03960840)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: Phase I/II Study o
 f Rapcabtagene Autoleucel in CLL\, 3L+ DLBCL\, r/r ALL and 1L HR LBCL\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03960840
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047118-10762@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:Luxdegalutamide: Phase 2 readout est. (NCT07047118)
DESCRIPTION:Luxdegalutamide\, phase 2\, Metastatic Castration-Resistant Pro
 state Cancer.\nStudy: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (1
 77Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resista
 nt Prostate Cancer (mCRPC)\nEstimated primary completion: 16 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/luxdegalutamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07047118
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06006559-11254@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:EYU688: Phase 2 readout est. (NCT06006559)
DESCRIPTION:EYU688\, phase 2\, Dengue.\nStudy: A Study to Assess the Effica
 cy\, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever\n
 Estimated primary completion: 22 July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/eyu688#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06006559
URL:https://assetmemo.bio/drug/eyu688#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632600-11263@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:LXE408: Phase 2 readout est. (NCT06632600)
DESCRIPTION:LXE408\, phase 2.\nStudy: A Study of Efficacy\, Safety\, Tolera
 bility of LXE408 in Participants With Chronic Chagas Disease.\nEstimated p
 rimary completion: 22 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lxe408#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06632600
URL:https://assetmemo.bio/drug/lxe408#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467993-9513@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270729
DTEND;VALUE=DATE:20270730
SUMMARY:GXV813: Phase 2 readout est. (NCT07467993)
DESCRIPTION:GXV813\, phase 2\, Schizophrenia.\nStudy: Study to Assess the S
 afety\, Tolerability\, and Treatment Response of GXV813 in Hospitalized Ad
 ults With Schizophrenia\nEstimated primary completion: 29 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gxv813#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07467993
URL:https://assetmemo.bio/drug/gxv813#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03040973-1968@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Capmatinib: Phase 2 readout est. (NCT03040973)
DESCRIPTION:Capmatinib\, phase 2.\nStudy: Study to Allow Patients Previousl
 y Participating in a Novartis Sponsored Trial to Continue Receiving Capmat
 inib Treatment as Single Agent or in Combination With Other Treatments or 
 the Combination Treatment Alone\nEstimated primary completion: 30 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capmatinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03040973
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470048-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:VAY736: Phase 2 readout est. (NCT06470048)
DESCRIPTION:VAY736\, phase 2.\nStudy: A Clinical Study to Evaluate Ianaluma
 b in Participants With Diffuse Cutaneous Systemic Sclerosis\nEstimated pri
 mary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/vay736#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06470048
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852938-909@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Zigakibart: Phase 3 readout est. (NCT05852938)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: A Study 
 of Zigakibart in Adults With IgA Nephropathy\nEstimated primary completion
 : 10 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zig
 akibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05852938
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865651-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270823
DTEND;VALUE=DATE:20270824
SUMMARY:remibrutinib: Phase 2 readout est. (NCT06865651)
DESCRIPTION:remibrutinib\, phase 2\, Chronic Spontaneous Urticaria.\nStudy:
  Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its
  Mechanism of Action in Participants With Chronic Urticaria\nEstimated pri
 mary completion: 23 August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/remibrutinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06865651
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217067-11267@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270909
DTEND;VALUE=DATE:20270910
SUMMARY:PKN605: Phase 2 readout est. (NCT07217067)
DESCRIPTION:PKN605\, phase 2\, Atrial Fibrillation.\nStudy: A Study to Inve
 stigate the Efficacy\, Safety\, Tolerability and Pharmacokinetics of PKN60
 5 in Participants With Atrial Fibrillation\nEstimated primary completion: 
 9 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pkn
 605#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07217067
URL:https://assetmemo.bio/drug/pkn605#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05126277-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270921
DTEND;VALUE=DATE:20270922
SUMMARY:VAY736: Phase 3 readout est. (NCT05126277)
DESCRIPTION:VAY736\, phase 3.\nStudy: Safety\, Efficacy and Tolerability of
  Ianalumab Versus Placebo\, Combination With SoC Therapy\, in Participants
  With Active Lupus Nephritis\nEstimated primary completion: 21 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05126277
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-7619@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT02955940)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: An Open-Label Study to 
 Enable Continued Treatment Access for Subjects Previously Enrolled in Stud
 ies of Ruxolitinib\nEstimated primary completion: 30 September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02955940
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747613-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04747613)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Long-term Safety and Tolerability of Iptacopan in Patients 
 With Paroxysmal Nocturnal Hemoglobinuria\nEstimated primary completion: 18
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iptaco
 pan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04747613
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797518-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271127
DTEND;VALUE=DATE:20271128
SUMMARY:Fabhalta (Iptacopan): Phase 2 readout est. (NCT06797518)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 2\, IgA Nephropathy.\nStudy: Study
  to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Ki
 dneys of Adult Patients With IgAN\nEstimated primary completion: 27 Novemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/iptacopan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067975
 18
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681271-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20271207
DTEND;VALUE=DATE:20271208
SUMMARY:remibrutinib: Phase 2 readout est. (NCT07681271)
DESCRIPTION:remibrutinib\, phase 2.\nStudy: A Phase 2 Study to Investigate 
 the Efficacy\, Safety and Tolerability of Remibrutinib (LOU064) in Adult P
 atients With Papulopustular Rosacea (PPR)\nEstimated primary completion: 7
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remib
 rutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07681271
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562466-3771@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:indacaterol maleate / mometasone furoate: Phase 3 readout est. (NCT
 05562466)
DESCRIPTION:indacaterol maleate / mometasone furoate\, phase 3\, Asthma.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol A
 cetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Th
 an 12 Years of Age With Asthma\nEstimated primary completion: 1 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/indacaterol-male
 ate-mometasone-furoate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05562466
URL:https://assetmemo.bio/drug/indacaterol-maleate-mometasone-furoate#upcom
 ing-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813911-1034@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06813911)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Backgrou
 nd Inclisiran in Participants With Elevated Lp(a) and Established ASCVD\nE
 stimated primary completion: 3 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06813911
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581198-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06581198)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2\, Lupus Nephritis.\nStudy: A 
 Study of Rapcabtagene Autoleucel in Active\, Refractory Systemic Lupus Ery
 thematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)\nEs
 timated primary completion: 14 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06581198
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597006-1034@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597006)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Safety\, Tolerability and Efficacy of I
 nclisiran in Children With Homozygous Familial Hypercholesterolemia\nEstim
 ated primary completion: 21 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/inclisiran#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06597006
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06597019-1034@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT06597019)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Study to Evaluate Efficacy and Safety of Inclisiran in Ch
 ildren With Heterozygous Familial Hypercholesterolemia\nEstimated primary 
 completion: 21 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/inclisiran#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06597019
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-330@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT04573478)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: Atra
 sentan in Patients With IgA Nephropathy\nEstimated primary completion: 14 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atrasenta
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 573478
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06546670-10298@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:ITU512: Phase 1/2 readout est. (NCT06546670)
DESCRIPTION:ITU512\, phase 1/2\, Sickle Cell Disease.\nStudy: A Phase I/II 
 Study of ITU512 in Healthy Participants and Patients With Sickle Cell Dise
 ase\nEstimated primary completion: 1 May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/itu512#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06546670
URL:https://assetmemo.bio/drug/itu512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06331312-91@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280508
DTEND;VALUE=DATE:20280509
SUMMARY:Cosentyx (secukinumab): Phase 3 readout est. (NCT06331312)
DESCRIPTION:Cosentyx (secukinumab)\, phase 3.\nStudy: Open-label\, Long-ter
 m Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)\nEstimated p
 rimary completion: 8 May 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/secukinumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06331312
URL:https://assetmemo.bio/drug/secukinumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816328-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07816328)
DESCRIPTION:remibrutinib\, phase 3\, Chronic Spontaneous Urticaria.\nStudy:
  Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm
  in Adult Patients With Chronic Spontaneous Urticaria Inadequately Control
 led by H1-antihistamines Within 24 Weeks\nEstimated primary completion: 24
  May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7816328
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05948943-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alpelisib (BYL719): Phase 2/3 readout est. (NCT05948943)
DESCRIPTION:Alpelisib (BYL719)\, phase 2/3.\nStudy: Alpelisib in Pediatric 
 and Adult Patients With Lymphatic Malformations Associated With a PIK3CA M
 utation.\nEstimated primary completion: 31 May 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05948943
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431177-1372@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:GIA632: Phase 2 readout est. (NCT07431177)
DESCRIPTION:GIA632\, phase 2\, Vitiligo.\nStudy: A Phase IIb Dose-ranging S
 tudy to Assess the Efficacy and Safety of GIA632 in Participants With Non-
 segmental Vitiligo\nEstimated primary completion: 6 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gia632#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07431177
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780670-11245@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280627
DTEND;VALUE=DATE:20280628
SUMMARY:225Ac-PSMA-617: Phase 2/3 readout est. (NCT06780670)
DESCRIPTION:225Ac-PSMA-617\, phase 2/3\, Prostate Cancer.\nStudy: Open-labe
 l Study Comparing AAA817 Versus Standard of Care in the Treatment of Previ
 ously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or
  After [177Lu]Lu-PSMA Targeted Therapy\nEstimated primary completion: 27 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/225ac-psma-
 617#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06780670
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226986-11246@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:AMO959: Phase 1/2 readout est. (NCT07226986)
DESCRIPTION:AMO959\, phase 1/2\, Prostate Cancer.\nStudy: A Phase Ib/II Ope
 n-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA61
 7) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
 \nEstimated primary completion: 10 July 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amo959#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07226986
URL:https://assetmemo.bio/drug/amo959#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05935215-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280721
DTEND;VALUE=DATE:20280722
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT05935215)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Efficacy and Safety of 
 Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study 
 Participants With Atypical Hemolytic Uremic Syndrome (aHUS)\nEstimated pri
 mary completion: 21 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/iptacopan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05935215
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07094516-700@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280914
DTEND;VALUE=DATE:20280915
SUMMARY:Lifonebart (VHB937): Phase 2 readout est. (NCT07094516)
DESCRIPTION:Lifonebart (VHB937)\, phase 2\, Alzheimer's Disease.\nStudy: A 
 Clinical Trial to Learn About the Effects of VHB937 in People With Early A
 lzheimer's Disease\nEstimated primary completion: 14 September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lifonebart-vhb937#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07094516
URL:https://assetmemo.bio/drug/lifonebart-vhb937#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850752-330@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280917
DTEND;VALUE=DATE:20280918
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT07850752)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: A St
 udy of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patient
 s With Primary IgA Nephropathy\nEstimated primary completion: 17 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/atrasentan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0785075
 2
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06726148-2228@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280925
DTEND;VALUE=DATE:20280926
SUMMARY:Ribociclib: Phase 1/2 readout est. (NCT06726148)
DESCRIPTION:Ribociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of ECI830 Single Agent or in Combination in Patients With Adva
 nced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tum
 ors\nEstimated primary completion: 25 September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ribociclib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06726148
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855277-11245@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280929
DTEND;VALUE=DATE:20280930
SUMMARY:225Ac-PSMA-617: Phase 3 readout est. (NCT06855277)
DESCRIPTION:225Ac-PSMA-617\, phase 3\, Prostate Cancer.\nStudy: Study Compa
 ring AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-p
 ositive mCRPC\nEstimated primary completion: 29 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/225ac-psma-617#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06855277
URL:https://assetmemo.bio/drug/225ac-psma-617#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03650114-6493@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ofatumumab: Phase 3 readout est. (NCT03650114)
DESCRIPTION:Ofatumumab\, phase 3\, Multiple Sclerosis.\nStudy: Long-term Sa
 fety\, Tolerability and Effectiveness Study of Ofatumumab in Patients With
  Relapsing MS\nEstimated primary completion: 30 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ofatumumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03650114
URL:https://assetmemo.bio/drug/ofatumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05755386-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT05755386)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Study of Efficacy and S
 afety of Iptacopan in Participants With IC-MPGN\nEstimated primary complet
 ion: 27 October 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /iptacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05755386
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07048197-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT07048197)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: A Study to Assess 
 Safety\, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autole
 ucel in Rheumatoid Arthritis and Sjogren's Disease\nEstimated primary comp
 letion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rapcabtagene-autoleucel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07048197
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775924-1372@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281122
DTEND;VALUE=DATE:20281123
SUMMARY:GIA632: Phase 2 readout est. (NCT07775924)
DESCRIPTION:GIA632\, phase 2.\nStudy: A Study to Assess the Efficacy and Sa
 fety of GIA632 Across a Range of Doses in Participants With Moderate to Se
 vere Cutaneous Lichen Planus\nEstimated primary completion: 22 November 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/gia632#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07775924
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947993-1371@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281127
DTEND;VALUE=DATE:20281128
SUMMARY:GHZ339: Phase 2 readout est. (NCT06947993)
DESCRIPTION:GHZ339\, phase 2\, Atopic Dermatitis.\nStudy: Platform Study to
  Evaluate the Efficacy and Safety of Investigational Compound(s) in Patien
 ts With Moderate to Severe Atopic Dermatitis\nEstimated primary completion
 : 27 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 hz339#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06947993
URL:https://assetmemo.bio/drug/ghz339#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06655896-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06655896)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2.\nStudy: Phase 2 Study Evalua
 ting Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous System
 ic Sclerosis\nEstimated primary completion: 30 November 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06655896
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801495-10879@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:MRT-6160: Phase 2 readout est. (NCT07801495)
DESCRIPTION:MRT-6160\, phase 2.\nStudy: A Study to Assess the Efficacy\, Sa
 fety and Tolerability of DDY391 in Participants With Moderate to Severe Ps
 oriatic Arthritis\nEstimated primary completion: 13 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/mrt-6160#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07801495
URL:https://assetmemo.bio/drug/mrt-6160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748624-11265@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20281226
DTEND;VALUE=DATE:20281227
SUMMARY:Arumakimig: Phase 2 readout est. (NCT07748624)
DESCRIPTION:Arumakimig\, phase 2.\nStudy: A 52-Week Study Evaluating the Ef
 ficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Follow
 ed by Open-Label Extension (OLE) Period\nEstimated primary completion: 26 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/arumak
 imig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07748624
URL:https://assetmemo.bio/drug/arumakimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421167-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290118
DTEND;VALUE=DATE:20290119
SUMMARY:VAY736: Phase 2 readout est. (NCT07421167)
DESCRIPTION:VAY736\, phase 2.\nStudy: A Study to Assess the Tolerability of
  Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Ago
 nist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)\nE
 stimated primary completion: 18 January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07421167
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997588-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT06997588)
DESCRIPTION:Alpelisib (BYL719)\, phase 2.\nStudy: EPIK-P4: A Phase II Singl
 e-arm Study to Assess the Efficacy\, Safety and Pharmacokinetics of Alpeli
 sib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowt
 h Spectrum (PROS)\nEstimated primary completion: 29 January 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06997588
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737743-10879@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290219
DTEND;VALUE=DATE:20290220
SUMMARY:MRT-6160: Phase 2 readout est. (NCT07737743)
DESCRIPTION:MRT-6160\, phase 2\, Sjögren's Disease.\nStudy: A Phase 2a/b S
 tudy to Assess the Efficacy\, Safety and Tolerability of DDY391 in Partici
 pants With Sjögren's Disease\nEstimated primary completion: 19 February 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-6160#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07737743
URL:https://assetmemo.bio/drug/mrt-6160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811869-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290226
DTEND;VALUE=DATE:20290227
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07811869)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: A Study to Evaluate Efficacy\, 
 Safety\, and Tolerability of Remibrutinib in Adult Participants With Sever
 e Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary completion:
  26 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 mibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07811869
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06665256-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290309
DTEND;VALUE=DATE:20290310
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06665256)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2.\nStudy: Phase 2 Study of Rap
 cabtagene Autoleucel in Myositis\nEstimated primary completion: 9 March 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rapcabtagene-auto
 leucel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06665256
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868328-766@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290326
DTEND;VALUE=DATE:20290327
SUMMARY:NIO752: Phase 2 readout est. (NCT07868328)
DESCRIPTION:NIO752\, phase 2\, Progressive Supranuclear Palsy.\nStudy: A St
 udy to Evaluate the Safety\, Tolerability and Pharmacodynamics of NIO752 i
 n Primary Tauopathies\nEstimated primary completion: 26 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nio752#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07868328
URL:https://assetmemo.bio/drug/nio752#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768371-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07768371)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: A 52-week Study of Remibrutinib
  in IgE-mediated Food Allergy\nEstimated primary completion: 30 March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07768371
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739383-1034@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290416
DTEND;VALUE=DATE:20290417
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05739383)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: A Study of Inclisiran to Prevent Cardiovascular Events in
  High-risk Primary Prevention Patients.\nEstimated primary completion: 16 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisira
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 739383
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03591510-2843@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290518
DTEND;VALUE=DATE:20290519
SUMMARY:Rydapt (Midostaurin): Phase 2 readout est. (NCT03591510)
DESCRIPTION:Rydapt (Midostaurin)\, phase 2\, Acute Myeloid Leukemia.\nStudy
 : A Global Study of Midostaurin in Combination With Chemotherapy to Evalua
 te Safety\, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Pat
 ients With FLT3 Mutated AML\nEstimated primary completion: 18 May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/midostaurin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03591510
URL:https://assetmemo.bio/drug/midostaurin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868290-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290607
DTEND;VALUE=DATE:20290608
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06868290)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2.\nStudy: Phase 2 Study Evalua
 ting Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
 \nEstimated primary completion: 7 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06868290
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468071-1979@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290611
DTEND;VALUE=DATE:20290612
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT07468071)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ro
 llover Study for Participants Who Have Been Treated With and Are Continuin
 g to Benefit From Opnurasib as a Single Agent or in Combination With Other
  Study Treatments\nEstimated primary completion: 11 June 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07468071
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920887-154@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:bimagrumab: Phase 2 readout est. (NCT07920887)
DESCRIPTION:bimagrumab\, phase 2.\nStudy: A Study of Bimagrumab in Particip
 ants With HFpEF\nEstimated primary completion: July 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bimagrumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07920887
URL:https://assetmemo.bio/drug/bimagrumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439082-10308@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:crizanlizumab-tmca (Adakveo): Phase 3 readout est. (NCT06439082)
DESCRIPTION:crizanlizumab-tmca (Adakveo)\, phase 3\, Sickle Cell Disease.\n
 Study: A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 
 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease P
 atients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)\nEstimated
  primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06439082
URL:https://assetmemo.bio/drug/crizanlizumab-tmca-adakveo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254482-11257@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Votoplam: Phase 2 readout est. (NCT06254482)
DESCRIPTION:Votoplam\, phase 2\, Huntington's Disease.\nStudy: An Extension
  Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Partic
 ipants With Huntington's Disease (HD)\nEstimated primary completion: 16 Ju
 ly 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/votoplam#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0625448
 2
URL:https://assetmemo.bio/drug/votoplam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498426-766@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:NIO752: Phase 3 readout est. (NCT07498426)
DESCRIPTION:NIO752\, phase 3\, Progressive Supranuclear Palsy.\nStudy: A St
 udy to Evaluate the Efficacy of NIO752 in Participants With Progressive Su
 pranuclear Palsy\nEstimated primary completion: 20 July 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nio752#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07498426
URL:https://assetmemo.bio/drug/nio752#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846281-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06846281)
DESCRIPTION:remibrutinib\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy a
 nd Safety of Remibrutinib After Switching From Ocrelizumab in Participants
  Living With Relapsing Multiple Sclerosis.\nEstimated primary completion: 
 25 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remibru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06846281
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621809-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:VAY736: Phase 3 readout est. (NCT07621809)
DESCRIPTION:VAY736\, phase 3\, Sjögren's Disease.\nStudy: Two Arm\, Double
 -blind\, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus
  Placebo\, in Participants With Sjögren's Disease With High Symptom Burde
 n\nEstimated primary completion: 15 August 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07621809
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441642-11255@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290821
DTEND;VALUE=DATE:20290822
SUMMARY:FWY003: Phase 2 readout est. (NCT07441642)
DESCRIPTION:FWY003\, phase 2\, Geographic Atrophy.\nStudy: A Study to Inves
 tigate Efficacy and Safety of FWY003 Compared With Placebo in Participants
  With Geographic Atrophy Secondary to Age-related Macular Degeneration\nEs
 timated primary completion: 21 August 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/fwy003#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07441642
URL:https://assetmemo.bio/drug/fwy003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827081-2228@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Ribociclib: Phase 3 readout est. (NCT05827081)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: Phase IIIb Study 
 of Ribociclib + ET in Early Breast Cancer\nEstimated primary completion: 7
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ribo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05827081
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704269-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291026
DTEND;VALUE=DATE:20291027
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT06704269)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: Study to Assess Sa
 fety\, Efficacy\, and Cellular Kinetics of YTB323 in Generalized Myastheni
 a Gravis\nEstimated primary completion: 26 October 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06704269
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206056-10762@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291109
DTEND;VALUE=DATE:20291110
SUMMARY:Luxdegalutamide: Phase 1/2 readout est. (NCT07206056)
DESCRIPTION:Luxdegalutamide\, phase 1/2.\nStudy: An Open-label Dose Escalat
 ion and Expansion\, Followed by a Phase II Study of Tulmimetostat (DZR123)
  and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Cast
 rate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)\nEstimated primary c
 ompletion: 9 November 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/luxdegalutamide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07206056
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923773-10879@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:MRT-6160: Phase 2 readout est. (NCT07923773)
DESCRIPTION:MRT-6160\, phase 2.\nStudy: Extension Study of Safety and Toler
 ability of DDY391 in Participants With Moderate to Severe Psoriatic Arthri
 tis (CDDY391A12201-extension)\nEstimated primary completion: 12 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mrt-6160#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07923773
URL:https://assetmemo.bio/drug/mrt-6160#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700056-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291219
DTEND;VALUE=DATE:20291220
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07700056)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: A Study to Evaluate Efficacy\, 
 Safety and Tolerability of Remibrutinib in Adult Participants With Severe 
 Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary completion: 1
 9 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remi
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07700056
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06401356-7619@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT06401356)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3.\nStudy: An Extension Study for 
 Patients Previously Enrolled in Studies With Pelabresib\nEstimated primary
  completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06401356
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517263-1038@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300109
DTEND;VALUE=DATE:20300110
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT07517263)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: An Open Label Extension (OLE) Study (Following Completion of CTQJ2
 30A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ
 230)\nEstimated primary completion: 9 January 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07517263
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05646381-1038@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300312
DTEND;VALUE=DATE:20300313
SUMMARY:Pelacarsen: Phase 2 readout est. (NCT05646381)
DESCRIPTION:Pelacarsen\, phase 2\, Atherosclerotic Cardiovascular Disease.\
 nStudy: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowerin
 g With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Ste
 nosis\nEstimated primary completion: 12 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pelacarsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05646381
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326709-11257@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300402
DTEND;VALUE=DATE:20300403
SUMMARY:Votoplam: Phase 3 readout est. (NCT07326709)
DESCRIPTION:Votoplam\, phase 3\, Huntington's Disease.\nStudy: A Study to I
 nvestigate the Efficacy\, Safety and Tolerability of Votoplam in Participa
 nts With Huntington's Disease\nEstimated primary completion: 2 April 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/votoplam#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07326709
URL:https://assetmemo.bio/drug/votoplam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701334-2228@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300529
DTEND;VALUE=DATE:20300530
SUMMARY:Ribociclib: Phase 3 readout est. (NCT03701334)
DESCRIPTION:Ribociclib\, phase 3\, Breast Cancer.\nStudy: A Trial to Evalua
 te Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Tr
 eatment in Patients With HR+/HER2- Early Breast Cancer\nEstimated primary 
 completion: 29 May 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ribociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03701334
URL:https://assetmemo.bio/drug/ribociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675864-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300614
DTEND;VALUE=DATE:20300615
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT06675864)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: Open-label\, Multi
 -center\, Phase I/II Study to Assess Safety\, Disease Progression and Cell
 ular Kinetics Following YTB323 Administration in Participants With Non-act
 ive Progressive Multiple Sclerosis (PMS)\nEstimated primary completion: 14
  June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rapcabtag
 ene-autoleucel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06675864
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994845-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06994845)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, IgA Nephropathy.\nStudy: Study
  to Assess the Efficacy\, Pharmacokinetics\, Safety and Tolerability of Ip
 tacopan in Pediatric Patients With Primary IgAN\nEstimated primary complet
 ion: 28 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 tacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06994845
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146906-909@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300712
DTEND;VALUE=DATE:20300713
SUMMARY:Zigakibart: Phase 2 readout est. (NCT07146906)
DESCRIPTION:Zigakibart\, phase 2\, Chronic Kidney Disease.\nStudy: A Study 
 to Assess the Effects of Zigakibart on IgA Nephropathy.\nEstimated primary
  completion: 12 July 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zigakibart#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07146906
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06617793-11270@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20300807
DTEND;VALUE=DATE:20300808
SUMMARY:Rapcabtagene autoleucel: Phase 1/2 readout est. (NCT06617793)
DESCRIPTION:Rapcabtagene autoleucel\, phase 1/2.\nStudy: An Open-label Stud
 y to Assess the Safety\, Efficacy\, and Cellular Kinetics of YTB323 in Rel
 apsing Multiple Sclerosis\nEstimated primary completion: 7 August 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rapcabtagene-autoleucel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066
 17793
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938411-949@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301022
DTEND;VALUE=DATE:20301023
SUMMARY:Pacibekitug: Phase 3 readout est. (NCT07938411)
DESCRIPTION:Pacibekitug\, phase 3.\nStudy: A Study to Assess the Effect of 
 Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial 
 Infarction\nEstimated primary completion: 22 October 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pacibekitug#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07938411
URL:https://assetmemo.bio/drug/pacibekitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225504-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301203
DTEND;VALUE=DATE:20301204
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07225504)
DESCRIPTION:remibrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive
  Multiple Sclerosis\nEstimated primary completion: 3 December 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07225504
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557462-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301204
DTEND;VALUE=DATE:20301205
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04557462)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Rollover Extension Program (REP) to Evaluate the Long-term Safety and 
 Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary I
 gA Nephropathy\nEstimated primary completion: 4 December 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04557462
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875973-1038@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301208
DTEND;VALUE=DATE:20301209
SUMMARY:Pelacarsen: Phase 3 readout est. (NCT06875973)
DESCRIPTION:Pelacarsen\, phase 3\, Atherosclerotic Cardiovascular Disease.\
 nStudy: Pelacarsen Roll-over Extension Program\nEstimated primary completi
 on: 8 December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pelacarsen#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06875973
URL:https://assetmemo.bio/drug/pelacarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739888-11264@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Abelacimab: Phase 3 readout est. (NCT07739888)
DESCRIPTION:Abelacimab\, phase 3.\nStudy: Study to Evaluate the effIcacy an
 d Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who 
 Have Been Deemed Unsuitable for Oral Anticoagulation\nEstimated primary co
 mpletion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/abelacimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07739888
URL:https://assetmemo.bio/drug/abelacimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615050-7619@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT06615050)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3\, Graft-versus-Host Disease.\nSt
 udy: A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant
  Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Re
 duced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transpl
 antation (BMT CTN 2203)\nEstimated primary completion: 17 January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06615050
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564401-11249@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310303
DTEND;VALUE=DATE:20310304
SUMMARY:DJI136: Phase 1/2 readout est. (NCT07564401)
DESCRIPTION:DJI136\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate DJI136\, a DLL3-targeted CAR-T Therapy\nEstimated primary comple
 tion: 3 March 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ji136#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07564401
URL:https://assetmemo.bio/drug/dji136#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543120-11268@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310507
DTEND;VALUE=DATE:20310508
SUMMARY:QCZ484: Phase 2 readout est. (NCT07543120)
DESCRIPTION:QCZ484\, phase 2\, Hypertension.\nStudy: An Open-label Extensio
 n Safety and Efficacy Study of QCZ484 in Hypertensive Patients.\nEstimated
  primary completion: 7 May 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/qcz484#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07543120
URL:https://assetmemo.bio/drug/qcz484#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288359-9035@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310509
DTEND;VALUE=DATE:20310510
SUMMARY:Letrozole: Phase 1/2 readout est. (NCT07288359)
DESCRIPTION:Letrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of GVV858 as a Single Agent or in Combination With Endocrine Th
 erapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tu
 mors\nEstimated primary completion: 9 May 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/letrozole#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07288359
URL:https://assetmemo.bio/drug/letrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06910813-11248@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310528
DTEND;VALUE=DATE:20310529
SUMMARY:DFT383: Phase 1/2 readout est. (NCT06910813)
DESCRIPTION:DFT383\, phase 1/2\, Cystinosis.\nStudy: DFT383 in Pediatric Pa
 rticipants With Nephropathic Cystinosis\nEstimated primary completion: 28 
 May 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dft383#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06910813
URL:https://assetmemo.bio/drug/dft383#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858319-909@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310625
DTEND;VALUE=DATE:20310626
SUMMARY:Zigakibart: Phase 3 readout est. (NCT06858319)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Open-lab
 el Extension Study of Zigakibart in Adults With IgA Nephropathy.\nEstimate
 d primary completion: 25 June 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/zigakibart#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06858319
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498335-330@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20310915
DTEND;VALUE=DATE:20310916
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT07498335)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: Stud
 y to Assess the Efficacy\, Pharmacokinetics\, Safety and Tolerability of A
 trasentan in Pediatric Patients With Primary IgAN\nEstimated primary compl
 etion: 15 September 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atrasentan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07498335
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934967-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20311014
DTEND;VALUE=DATE:20311015
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06934967)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study to Assess the Pharmacokinetics\, Safety\, and Tolerab
 ility of Iptacopan in Pediatric PNH Patients\nEstimated primary completion
 : 14 October 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 tacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06934967
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665437-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20311015
DTEND;VALUE=DATE:20311016
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07665437)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: An E
 xtension Study to Assess Safety and Efficacy of Remibrutinib in Participan
 ts With Moderate to Severe HS\nEstimated primary completion: 15 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07665437
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679269-3247@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320323
DTEND;VALUE=DATE:20320324
SUMMARY:Alpelisib (BYL719): Phase 2 readout est. (NCT07679269)
DESCRIPTION:Alpelisib (BYL719)\, phase 2\, HR+/HER2- Metastatic Breast Canc
 er.\nStudy: Roll-Over Study of Alpelisib (BYL719) for Continued Access and
  Long-Term Safety.\nEstimated primary completion: 23 March 2032. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/alpelisib-byl719#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07679269
URL:https://assetmemo.bio/drug/alpelisib-byl719#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05682378-1034@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320325
DTEND;VALUE=DATE:20320326
SUMMARY:Leqvio (Inclisiran): Phase 3 readout est. (NCT05682378)
DESCRIPTION:Leqvio (Inclisiran)\, phase 3\, Atherosclerotic Cardiovascular 
 Disease.\nStudy: Long-term Safety and Tolerability of Inclisiran in Partic
 ipants With HeFH or HoFH Who Have Completed the Pediatric ORION-16\, ORION
 -13\, ORION-20\, or ORION-19 Studies\nEstimated primary completion: 25 Mar
 ch 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/inclisiran#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05682
 378
URL:https://assetmemo.bio/drug/inclisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05795140-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20320716
DTEND;VALUE=DATE:20320717
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT05795140)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Evaluate Long-term Safe
 ty\, Tolerability and Efficacy of Iptacopan in Study Participants With aHU
 S\nEstimated primary completion: 16 July 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/iptacopan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05795140
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07456891-1415@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330130
DTEND;VALUE=DATE:20330131
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07456891)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: Remibrutinib Open Label Roll-ov
 er Post-trial Access Protocol\nEstimated primary completion: 30 January 20
 33. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07456891
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660172-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330422
DTEND;VALUE=DATE:20330423
SUMMARY:VAY736: Phase 2 readout est. (NCT07660172)
DESCRIPTION:VAY736\, phase 2.\nStudy: A Study of Ianalumab in Addition to E
 ltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroi
 ds.\nEstimated primary completion: 22 April 2033. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07660172
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985915-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20330422
DTEND;VALUE=DATE:20330423
SUMMARY:VAY736: Phase 3 readout est. (NCT05985915)
DESCRIPTION:VAY736\, phase 3.\nStudy: A Randomized\, Double-blind 2-arm\, F
 ollowed by an Open-label 1-arm\, NEPTUNUS Extension Study to Assess the Lo
 ng-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrom
 e.\nEstimated primary completion: 22 April 2033. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vay736#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05985915
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06133972-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20340403
DTEND;VALUE=DATE:20340404
SUMMARY:VAY736: Phase 3 readout est. (NCT06133972)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase 3 Extension Study to Evaluate L
 ong-term Safety of Ianalumab in Participants With Systemic Lupus Erythemat
 osus (SIRIUS-SLE Extension).\nEstimated primary completion: 3 April 2034. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/vay736#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06133972
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711887-10731@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20350801
DTEND;VALUE=DATE:20350802
SUMMARY:VAY736: Phase 3 readout est. (NCT06711887)
DESCRIPTION:VAY736\, phase 3.\nStudy: Phase III Extension Study of Efficacy
  and Safety of Ianalumab With or Without Study Treatment Withdrawal in Par
 ticipants With Lupus Nephritis (SIRIUS-LN Extension)\nEstimated primary co
 mpletion: 1 August 2035. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/vay736#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06711887
URL:https://assetmemo.bio/drug/vay736#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03955445-887@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20360530
DTEND;VALUE=DATE:20360531
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT03955445)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3.\nStudy: Long-term Efficacy\, Sa
 fety and Tolerability of Iptacopan in C3G or IC-MPGN\nEstimated primary co
 mpletion: 30 May 2036. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/iptacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03955445
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
